Research Partnership has been ranked in the Pharma Times Pharma Fast 50
Industry Magazine Pharma Times has partnered with Catalyst Corporate Finance to publish a detailed analysis of the 50 fastest growing private, independently owned pharma companies in the UK and Research Partnership has been listed top 3 in the consulting category.
Research Partnership has published a new Living with Lupus (SLE) market report for 2017
SLE is a progressive and debilitating disease which affects 5 million people worldwide. Living with Lupus (SLE) is a quantitative study conducted online amongst patients in the US, France and Germany. The report consists of 30-minute online interviews with 262 SLE patients (including those with lupus nephritis); fifteen follow-up qualitative interviews were also conducted. All patients were required to be on an immunosuppressant or biologic therapy; the final sample includes 15-20% on biologics.
Research Partnership makes annual donation to Forever Projects
We are delighted to announce that Research Partnership has made a seasonal donation of US$5,000 to our chosen charity, Forever Projects. Fundraising efforts by our employees throughout the year contributed to this total.
Forever Projects is committed to providing support to young children in Tanzania. This wonderful charity provides nutrition and loving, holistic care to needy children, helping to preserve the family wherever possible. Their two main projects are Forever Angels Baby Home and Maisha Matters - a community outreach program which provides orphan babies with life-saving formula milk in their own homes and helps their relatives set up a sustainable business so they can support their families into the future.
Research Partnership has published a new Living with Chronic Pain market report for 2016
Chronic pain is defined as pain lasting longer than 6 months and affects 100 million Americans. Living with Chronic Pain is a quantitative study conducted online amongst 390 US patients with diabetic neuropathic pain, chronic lower back pain, cancer pain and headache/migraine pain. At least 60% of the patients surveyed are currently prescribed long acting opioids (LAOs). The report can be purchased for all four pain types, or for one individual pain type only.
Research Partnership has published a new Living with Ulcerative Colitis (UC) market report for 2016.
Ulcerative Colitis (UC) is a progressive and debilitating disease which affects between 2.5 to 3 million people in Europe. Living with UC is a quantitative study conducted online amongst 325 patients, including both adult and paediatric patients diagnosed with ulcerative colitis in 5 EU markets (France, Germany, Italy, Spain and the UK).